[go: up one dir, main page]

NO20053010L - Flytende farmasoytiske preparater inneholdende 3,7- diazabisyklo [3,3,1] nonaner for behandling av anti- arytmiske hendelser. - Google Patents

Flytende farmasoytiske preparater inneholdende 3,7- diazabisyklo [3,3,1] nonaner for behandling av anti- arytmiske hendelser.

Info

Publication number
NO20053010L
NO20053010L NO20053010A NO20053010A NO20053010L NO 20053010 L NO20053010 L NO 20053010L NO 20053010 A NO20053010 A NO 20053010A NO 20053010 A NO20053010 A NO 20053010A NO 20053010 L NO20053010 L NO 20053010L
Authority
NO
Norway
Prior art keywords
antiarrhythmic
diazabicyclo
events
treatment
liquid pharmaceutical
Prior art date
Application number
NO20053010A
Other languages
English (en)
Inventor
Claus Rudolf Steinborn
Werner Cautreels
Matthias Straub
Johannes Wilhelmus Catharine Maria Jansen
Michiel Henricus De Vries
Original Assignee
Abbott Products Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Products Gmbh filed Critical Abbott Products Gmbh
Publication of NO20053010L publication Critical patent/NO20053010L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelsen av 3,7-diazabisyklo[3,3,1]nonanforbindelser, fortrinnsvis av 9,9-alkylen-3,7diazabisyklo[3,3,1]nonan-forbindelser, og mest foretrukket anvendelsen av tedisamil, og de fysiologisk akseptable syreaddisjonssaltene og/eller solvatene derav, i form av et flytende farmasøytisk preparat for behandling og/eller profylakse av anti-arytmiske hendelser hos menneskepasienter, fortrinnsvis ved omstilling av nylig oppstart av atrieflimmer (Afib) eller hjertebank til normal sinusrytme (NSR) hos menneskepasienter. Dessuten vedrører oppfinnelsen en fremgangsmåte for behandlinger, og farmasøytiske produkter.
NO20053010A 2002-11-18 2005-06-20 Flytende farmasoytiske preparater inneholdende 3,7- diazabisyklo [3,3,1] nonaner for behandling av anti- arytmiske hendelser. NO20053010L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42679502P 2002-11-18 2002-11-18
PCT/EP2003/012844 WO2004045591A2 (en) 2002-11-18 2003-11-17 Liquid pharmaceutical formulations containing 3,7-diazabicyclo`3,3,1! nonanes for treating anti-arrhythmic events

Publications (1)

Publication Number Publication Date
NO20053010L true NO20053010L (no) 2005-06-20

Family

ID=32326429

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053010A NO20053010L (no) 2002-11-18 2005-06-20 Flytende farmasoytiske preparater inneholdende 3,7- diazabisyklo [3,3,1] nonaner for behandling av anti- arytmiske hendelser.

Country Status (20)

Country Link
US (2) US7087620B2 (no)
EP (1) EP1565239B8 (no)
JP (1) JP2006510613A (no)
KR (1) KR101059330B1 (no)
CN (1) CN1726062A (no)
AR (1) AR042199A1 (no)
AT (1) ATE501758T1 (no)
AU (1) AU2003296580B8 (no)
BR (1) BR0316383A (no)
CA (1) CA2506083A1 (no)
DE (1) DE60336417D1 (no)
IL (1) IL168630A (no)
MX (1) MXPA05005344A (no)
NO (1) NO20053010L (no)
RU (1) RU2358732C2 (no)
SA (1) SA04250023B1 (no)
TW (1) TW200418468A (no)
UA (1) UA85546C2 (no)
WO (1) WO2004045591A2 (no)
ZA (1) ZA200504049B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
US20050054667A1 (en) * 2003-07-21 2005-03-10 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting anti-arrhythmic events in male human patients
AU2004260624A1 (en) * 2003-07-21 2005-02-10 Solvay Pharmaceuticals Gmbh Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
JPWO2007023775A1 (ja) * 2005-08-23 2009-02-26 アステラス製薬株式会社 心房細動治療剤
EP2149370A1 (en) * 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3361244D1 (de) * 1982-01-29 1986-01-02 Ici Plc Alkanolamine derivatives
DE3234697A1 (de) * 1982-09-18 1984-03-22 Kali-Chemie Pharma Gmbh, 3000 Hannover Neue diazabicyclo-(3,3,1)-nonane
PT88381B (pt) * 1987-09-09 1995-07-06 Kali Chemie Pharma Gmbh Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos
DE4019080A1 (de) * 1990-06-15 1991-12-19 Kali Chemie Pharma Gmbh Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel
DE4139763A1 (de) * 1991-12-03 1993-06-09 Kali-Chemie Pharma Gmbh, 3000 Hannover, De Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel
DE4402931A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Phenylsulfonyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
US5576349A (en) * 1995-11-30 1996-11-19 The General Hospital Corporation Retionoic acid treatment of cardiac arrhythmia
US6026817A (en) * 1996-11-14 2000-02-22 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
DE10131217A1 (de) * 2001-06-28 2003-01-09 Solvay Pharm Gmbh 3-Phenyl-3,7-diazabicyclo 3,3,1 nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events

Also Published As

Publication number Publication date
KR101059330B1 (ko) 2011-08-24
US7087620B2 (en) 2006-08-08
US20040152716A1 (en) 2004-08-05
ATE501758T1 (de) 2011-04-15
AU2003296580B8 (en) 2010-03-18
AU2003296580A1 (en) 2004-06-15
SA04250023B1 (ar) 2008-12-23
DE60336417D1 (de) 2011-04-28
JP2006510613A (ja) 2006-03-30
WO2004045591A3 (en) 2004-07-22
TW200418468A (en) 2004-10-01
WO2004045591A2 (en) 2004-06-03
BR0316383A (pt) 2005-10-04
EP1565239B1 (en) 2011-03-16
US20050261300A1 (en) 2005-11-24
ZA200504049B (en) 2006-07-26
CA2506083A1 (en) 2004-06-03
CN1726062A (zh) 2006-01-25
UA85546C2 (en) 2009-02-10
MXPA05005344A (es) 2005-08-03
RU2005119280A (ru) 2006-03-20
EP1565239A2 (en) 2005-08-24
AR042199A1 (es) 2005-06-15
IL168630A (en) 2013-08-29
AU2003296580B2 (en) 2010-02-18
KR20050116125A (ko) 2005-12-09
EP1565239B8 (en) 2011-06-22
RU2358732C2 (ru) 2009-06-20

Similar Documents

Publication Publication Date Title
Parker et al. Nitroglycerin lingual spray: clinical efficacy and dose-response relation
NO951498L (no) Farmasöytisk preparat for behandling av osteoporose
KR0128057B1 (ko) 피부 미소순환에 작용하는 약리적 조성물
NO20053010L (no) Flytende farmasoytiske preparater inneholdende 3,7- diazabisyklo [3,3,1] nonaner for behandling av anti- arytmiske hendelser.
Bucknall et al. Mianserin and trazodone for cardiac patients with depression
Risenfors et al. Prehospital thrombolysis in suspected acute myocardial infarction: results from the TEAHAT Study
ES2207486T3 (es) Preparacion para verrugas.
MXPA06000796A (es) Uso de los compuestos 3,7-diazabiciclo [3,3,1]nonano para el tratamiento y/o profilaxis de eventos antiarritmicos en pacientes humanos varones.
Lacourciere Analysis of well-being and 24-hour blood pressure recording in a comparative study between indapamide and captopril
Hill et al. Effect of bepridil in patients with chronic stable angina: results of a multicenter trial.
James et al. Baroreflex sensitivity changes with calcium antagonist therapy in elderly subjects with isolated systolic hypertension
Knilans et al. Antiarrhythmic drug therapy in the management of cardiac arrest survivors
Oral et al. Comparison of amiodarone versus ibutilide for the prevention of immediate recurrences of atrial fibrillation during pulmonary vein isolation
Chughtai et al. Carotid sinus syncope: Report of two cases
Leonetti et al. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial
Brown et al. Treatment of Cardiac Arrhythmias with Synchronized Electrical Counter-shock
Hubner et al. Assessment of dermal glyceryl trinitrate and isosorbide dinitrate for patients with angina pectoris.
Poncelet et al. A double-blind, randomized, comparative study of nitrendipine and enalapril in elderly hypertensive patients
TH84974A (th) สูตรผสมเภสัชภัณฑ์ชนิดของเหลวซึ่งมีสารประกอบ 3,7-ไดอะซาไบไซโคล [3,3,1] โนเนนและวิธีการของการทรีตเมนท์ซึ่งเกี่ยวข้องกับปรากฏการณ์ภาวะหัวใจเต้นผิดจังหวะ
NO952426L (no) Nytt legemiddel som inneholder 3,7-diazabisyklo[3,3,1Ånonan forbindelser
Prandota et al. Long QT syndrome precipitated by atropine and hypokalemia
Olvera et al. Efficacy and tolerability of amlodipine in patients with MILD-to-moderate hypertension
Chambers et al. Familial sudden death syndrome with an abnormal signal-averaged electrocardiogram as a potential marker
Munkhtuya Potentials for patients with severe arterial hypertension, by using antihypertensive pharmacotherapy combined with ozone therapy and nasal laser therapy.
SM Study of the comparative effect of verapamil and captopril on exercise tolerance in patients with essential hypertension

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application